Immune response to hepatitis A vaccine in liver transplanted children

The humoral immunogenicity of hepatitis A vaccine series in children after liver transplantation

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220110001

Enrollment

Registered

2022-01-10

Start date

2022-01-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunity to hepatitis A virus can protect hepatitis A infection especially in immunocompromised host suc as liver transplanted children Immunity, hepatitis A, vaccine, children, liver transplantation

Interventions

We give Hepatitis A vaccine (0.5 mL) to children after liver transplant who had hepatitis A antibody less than 10 mIU/mL for 2 doses (at the beginning at 6 months). Blood for hepatitis A antibody and

Active Comparator Drug

Hepatitis A vaccine

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: liver transplanted patients aged less than 18 years old, hepatitis A antibody less than 10 mIU/mL, healthy/no fever at the time of enrollment and underwent liver transplantation for more than 6 months

Exclusion criteria

Exclusion criteria: patients have acute illness, fever BT> 37.8 C or underwent liver transplantation for less than 6 months.

Design outcomes

Primary

Measure	Time frame
hepatitis A antibody 0, 6, 9, 12 months mIU/mL,Cellular T cell study 0, 6, 9, 12 months interferon gamma	—

Secondary

Measure	Time frame
Safety of hepatitis A vaccine day 1-7 after vaccination Adverse reactions	—

Countries

Thailand

Contacts

Public ContactPornthip Sinthavanuruk

Chulalongkorn University

pornthip.si@chula.ac.th022564455

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026